Showing 671-680 of 7446 results for "".
A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fOvercoming Adherence Challenges in the Management of Teen Acne
https://practicaldermatology.com/topics/practice-management/overcoming-adherence-challenges-in-the-management-of-teen-acne/20591/Adherence to acne treatment regimens is notoriously low among pre-teens and adolescents. Here's how to change that.Finding and Taking Advantage of Your Employees' Strengths
https://practicaldermatology.com/topics/practice-management/finding-and-taking-advantage-of-your-employees-strengths/20435/Tips for successfully incorporating a strength-based approach to staff management.Therapeutics Update: Notable Approvals in 2017
https://practicaldermatology.com/topics/skin-cancer-photoprotection/therapeutics-update-notable-approvals-in-2017/20398/A look at the newest additions to the medicine chest.Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sUpdates on NMSC, Zika, Aesthetics from Summer AAD Meeting
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-updates-on-nmsc-zika-aesthetics-from-summer-aad-meeting/18735/From the dermatologist's role in preparing for Zika to the latest advancements in aesthetics, the Summer meeting of the American Academy of Dermatology in Boston offered fresh insights for practitioners. Get updates on AK Management, the Zika risk, dermatologic care for nursing mothers, fillers, andTelemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andBONT-A Extends Fillers; Almirall to Acquire Thermi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-bont-a-extends-fillers-almirall-to-acquire-thermi/18648/In this edition of DermWireTV, a look at new data showing that injections with botulinum neurotoxin can extend the efficacy of hyaluronic acid fillers. The American Academy of Dermatology Association offers more response to the USPSTF draft recommendation on the benefits of skin exams for melanoma.Approvals in Psoriasis and Skin Cancer Highlight a Year of Innovation in Skin Disease Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/approvals-in-psoriasis-and-skin-cancer-highlight-a-year-of-innovation-in-skin-disease-management/21069/After periods of low drug approval rates, the last year brought several new agents to market.Electronic Brachytherapy: Understanding the Technology and Identifying Appropriate Use
https://practicaldermatology.com/topics/practice-management/electronic-brachytherapy-understanding-the-technology-and-identifying-appropriate-use/21148/The following information is for dermatology practices concerning Appropriate Use Criteria (AUC) for Electronic Brachytherapy.